Notice of AGM, Annual Report and Accounts

Sareum Holdings PLC

("Sareum" or the "Company")

Notice of AGM, Annual Report and Accounts

Cambridge, UK, 17 November 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, today announces that the Company's Annual General Meeting ("AGM") will be held at 10.00am GMT on Tuesday 9 December 2025 at the offices of ICR Healthcare, 85 Gresham Street, London EC2V 7NQ.

In order to allow shareholders to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company ("IMC") platform. Shareholders who wish to attend the AGM remotely should register for the event in advance by using the following link: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor. Investors who already follow Sareum Holdings plc on the IMC platform will automatically be invited.

Shareholders are invited to submit questions for the Board to consider in the Q&A session to be held immediately after the AGM. Questions can be pre submitted via the IMC Platform up until 8 December 2025, 9.00am GMT and can be submitted at any time during the AGM itself. Shareholders are reminded that they will not be able to vote online at the AGM via the IMC platform and are therefore requested to submit their votes via proxy, as early as possible.

Shareholders intending to vote should submit their vote online via the Investor Centre app or at https://uk.investorcentre.mpms.mufg.com/ where details of the procedure are shown. If you have not done so already, you will need to register your account using your Investor Code, which can be found on your share certificate. If you hold your shares in CREST and wish to vote via the Investor Centre rather than the CREST electronic proxy appointment services please contact our registrars, MUFG Corporate Markets to obtain your Investor Code (via email at [email protected] or call the registrars' helpline on 0371 664 0300, calls are charged at the standard geographic rate and will vary by provider; if you are outside the United Kingdom, please call +44 371 664 0300, calls will be charged at the applicable international rate). Alternatively, you may request a paper form of proxy from our registrars. 

The notice of AGM, along with a copy of the Company's annual report and accounts for the year ended 30 June 2025, will be posted shortly to those shareholders who requested a hard copy. A copy of both documents will also be available on the Company's website: www.sareum.com in the Investor Relations section.

For further information: 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy, and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease.

The Company is the license holder for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com